

DAFTAR PUSTAKA

- Ahn, B.C. *et al.* (2013) 'Estimation of true serum thyroglobulin concentration using simultaneous measurement of serum antithyroglobulin antibody', *International Journal of Endocrinology*, 2013. Available at: <https://doi.org/10.1155/2013/210639>.
- Ain, K., and Rosenthal, M.S. (2011) *The Complete Thyroid Book*. 2nd ed. New York: McGraw-Hill.
- Arista, R.Dwi., *et al.* (2023) 'Thyroid Cancer : an Overview of Epidemiology, Risk Factor, and Treatment', *Lombok Medical Journal*, 2(3), pp. 90–96. Available at: <https://doi.org/10.29303/lmj.v2i2.2791>.
- Berlińska, Agata., and Stodulska, R.Ś. (2024) 'Clinical use of thyroglobulin: not only thyroid cancer', *Endocrine Journal*, 84, pp. 786–799. Available at: <https://doi.org/10.1007/s12020-023-03658-3>.
- Crnčić, T.Bogović., *et al.* (2020) 'Risk factors for thyroid cancer: What do we know so far?', *Acta Clinica Croatica Journal*, 59, pp. 66–72. Available at: <https://doi.org/10.20471/acc.2020.59.s1.08>.
- Derwahl, M. and Nicula, D. (2014) 'Estrogen and its role in thyroid cancer', *Endocrine-Related Cancer*, 21(5), pp. T273–T283. Available at: <https://doi.org/10.1530/ERC-14-0053>.
- Đorić, I. *et al.* (2024) 'Advancing Immunoassay Precision: A Novel Preanalytical Method for Enhancing Thyroglobulin Measurement in the Presence of Tg Antibodies', *International Journal of Molecular Sciences*, 25(24). Available at: <https://doi.org/10.3390/ijms252413252>.
- Dyke, M. Van *et al.* (2015) 'Evaluation of Toxicological Hazards from Medical Radioiodine Administration', *Journal of Medical Toxicology*, 11, pp. 96–101. Available at: <https://doi.org/10.1007/s13181-014-0412-5>.
- Giovanella, L. *et al.* (2023) 'Thyroglobulin and thyroglobulin antibody: an updated clinical and laboratory expert consensus', *European Journal of Endocrinology*. BioScientifica Ltd., pp. R11–R27. Available at: <https://doi.org/10.1093/ejendo/lvad109>.
- Hall, L.T. (2023) *Molecular imaging and therapy*, *Molecular Imaging and Therapy*. Brisbane: Exon Publications. Available at: <https://doi.org/10.36255/molecular-imaging>.
- Haugen, B.R., *et al.* (2016) '2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer', *Thyroid*, 26(1), pp. 1–133. Available at: <https://doi.org/10.1089/thy.2015.0020>.

- IARC (2024) *Global Cancer Observatory: Cancer Today. Indonesia - GLOBOCAN 2022 Data, International Agency for Research on Cancer*. Available at: <https://gco.iarc.who.int/today> (Accessed: 29 July 2025).
- Ignjatovic, V., Matovic, M. and Vukomanovic, V. (2020) 'Comparison Of Thyroglobulin Concentrations Measured By Two Immunoradiometric Assay', *Serbian Journal of Experimental and Clinical Research*, 21(2), pp. 121–125. Available at: <https://doi.org/10.2478/SJECR-2018-0031>.
- Indrasena, B.S.H. (2017) 'Use of thyroglobulin as a tumour marker', *World Journal of Biological Chemistry*, 8(1), p. 81. Available at: <https://doi.org/10.4331/wjbc.v8.i1.81>.
- Jammah, A.A. *et al.* (2021) 'Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial', *Frontiers in Endocrinology*, 11. Available at: <https://doi.org/10.3389/fendo.2020.603432>.
- Jo, K. and Lim, D.J. (2018) 'Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer', *Korean Journal of Internal Medicine*, 33(6), pp. 1050–1057. Available at: <https://doi.org/10.3904/kjim.2018.289>.
- Kim, H.K. *et al.* (2020) 'The clinical meaning of pre-and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer', *Korean Journal of Internal Medicine*, 35(5), pp. 1164–1172. Available at: <https://doi.org/10.3904/kjim.2018.173>.
- Liu, Y. *et al.* (2023) 'Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy', *Drug Resistance Updates*. Churchill Livingstone. Available at: <https://doi.org/10.1016/j.drug.2023.100939>.
- Park, H. *et al.* (2025) 'Clinical Utility of Liquid Chromatography-Tandem Mass Spectrometry for Thyroglobulin Measurement in Comparison with Immunoradiometric Assay and Chemiluminescence Microparticle Immunoassay', *Endocrinology and Metabolism* [Preprint]. Available at: <https://doi.org/10.3803/enm.2025.2413>.
- Petrovic, I. *et al.* (2024) 'Influence of Thyroglobulin Autoantibodies on Thyroglobulin Levels Measured by Different Methodologies: IMA, LC-MS/MS, and RIA', *Journal of Clinical Endocrinology and Metabolism*, 109(12), pp. 3254–3263. Available at: <https://doi.org/10.1210/clinem/dgae286>.
- Song, M. *et al.* (2018) 'Response Prediction of Altered Thyroglobulin Levels After Radioactive Iodine Therapy Aided by Recombinant Human Thyrotropin in Patients with Differentiated Thyroid Cancer', *Nuclear Medicine and*

Molecular Imaging, 52(4), pp. 287–292. Available at: <https://doi.org/10.1007/s13139-018-0528-7>.

Spencer, C. and Fatemi, S. (2013) ‘Thyroglobulin antibody (TgAb) methods - Strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer’, *Best Practice and Research: Clinical Endocrinology and Metabolism*, pp. 701–712. Available at: <https://doi.org/10.1016/j.beem.2013.07.003>.

Spencer, C. and Petrovic, I. (2010) ‘Thyroglobulin Measurement’. Springer Science, pp. 125–153. Available at: https://doi.org/10.1007/978-1-4419-1485-9_7.

Sugiyono (2017) *Metode Penelitian Kuantitatif, Kualitatif, dan R&D*. Bandung: CV. Alfabeta.

Sugiyono (2021) *Metode Penelitian Kuantitatif, Kualitatif, dan R&D*. Bandung: Alfabeta.

Sugiyono (2022) *Metode penelitian kuantitatif, kualitatif, dan R&D*. 2nd ed. Bandung: Alfabeta.

Sung, H. *et al.* (2021) ‘Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, *CA: A Cancer Journal for Clinicians*, 71(3), pp. 209–249. Available at: <https://doi.org/10.3322/caac.21660>.

Sutari, S. *et al.* (2018) ‘Optimization of Thyroglobulin Coated Tube for Thyroglobulin IRMA Kit’, *JKPK (Jurnal Kimia dan Pendidikan Kimia)*, 3(2), p. 73. Available at: <https://doi.org/10.20961/jkpk.v3i2.22400>.

Toubeau, M. *et al.* (2004) ‘Predictive Value for Disease Progression of Serum Thyroglobulin Levels Measured in the Postoperative Period and After 131 I Ablation Therapy in Patients with Differentiated Thyroid Cancer’, *The Journal of Nuclear Medicine*, 45, pp. 988–994.

Widayati, P. *et al.* (2014) ‘Validasi Kit Immunoradimetricassay Free Prostate Spesific Antigen Untuk Pemantauan Pembesaran Prostat Jinak Secara In Vitro’, *Prosiding Pertemuan Ilmiah Radiosotop, Radiofarmaka, Siklotron dan Kedokteran Nuklir Tahun 2014*, pp. 65–70.

Xu, J. *et al.* (2015) ‘Thyroglobulin antibody resolution after total thyroidectomy for cancer’, *Journal of Surgical Research*, 198(2), pp. 366–370. Available at: <https://doi.org/10.1016/j.jss.2015.03.094>.

Zavala, L.F. *et al.* (2019) ‘In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation’, *Archives of Endocrinology and Metabolism*, 63(3), pp. 293–299. Available at: <https://doi.org/10.20945/2359-3997000000123>.

- Zhang, D. *et al.* (2018) 'Impact of Gender and Age on the Prognosis of Differentiated Thyroid Carcinoma: a Retrospective Analysis Based on SEER', *Hormones and Cancer*, 9(5), pp. 361–370. Available at: <https://doi.org/10.1007/s12672-018-0340-y>.
- Zhao, Y. *et al.* (2024) 'Prognostic value of postoperative anti-thyroglobulin antibody in patients with differentiated thyroid cancer', *Frontiers in Endocrinology*, 15. Available at: <https://doi.org/10.3389/fendo.2024.1354426>.